A digital inhaler uncovering patterns of SABA use in asthma and COPD Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020
COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Source: Eur Respir J 2002; 19: 246-251 Year: 2002
Comparison of inhaler and nebuliser bronchodilator treatments in COPD attacks Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002
The effect of inhaler switching on asthma and COPD patients Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 54s Year: 2001
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016
Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Nighttime short-acting beta-agonist (SABA) in asthma and COPD Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004